Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 1,249,026 | 773,689 | 594,189 | 593,166 | 500,919 |
| Cost of Goods | 200,154 | 142,953 | 71,041 | 102,817 | 85,905 |
| Gross Profit | 1,048,872 | 630,736 | 523,148 | 490,349 | 415,014 |
| Operating Expenses | 681,044 | 647,888 | 505,112 | 596,325 | 492,824 |
| Operating Income | 367,982 | -16,199 | 18,077 | -105,159 | -76,905 |
| Interest Expense | 44,398 | 40,246 | 38,646 | 38,971 | 34,376 |
| Other Income | -84,615 | 21,087 | -21,027 | -49,828 | 2,618 |
| Pre-tax Income | 238,969 | -35,358 | -41,596 | -193,958 | -108,663 |
| Income Tax | -12,115 | 30,919 | 15,883 | -110,195 | 2,907 |
| Net Income Continuous | 251,084 | -66,277 | -57,479 | -83,763 | -111,570 |
| Net Income | $251,084 | $-66,277 | $-57,479 | $-83,763 | $-111,570 |
| EPS Basic Total Ops | 1.91 | -0.51 | -0.44 | -0.66 | -0.87 |
| EPS Basic Continuous Ops | 1.91 | -0.51 | -0.44 | -0.66 | -0.87 |
| EPS Diluted Total Ops | 1.84 | -0.51 | -0.44 | -0.66 | -0.87 |
| EPS Diluted Continuous Ops | 1.83 | -0.51 | -0.44 | -0.66 | -0.87 |
| EPS Diluted Before Non-Recurring Items | 1.84 | -0.52 | -0.44 | -0.65 | -0.87 |
| EBITDA(a) | $381,785 | $-2,255 | $32,482 | $-90,991 | $-62,923 |